Singapore markets closed

BioNTech SE (BNTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
86.71-1.38 (-1.57%)
At close: 04:00PM EDT
87.16 +0.45 (+0.52%)
Pre-market: 08:47AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close88.09
Open87.95
Bid86.69 x 300
Ask86.77 x 300
Day's range86.15 - 88.24
52-week range85.21 - 125.83
Volume438,075
Avg. volume593,175
Market cap20.896B
Beta (5Y monthly)0.23
PE ratio (TTM)21.15
EPS (TTM)4.10
Earnings date06 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend date02 Jun 2022
1y target est118.53
  • The Telegraph

    Wall Street plunges after US inflation shock

    US stock markets plunged amid fears of stagflation in the American economy, which grew at its slowest pace in nearly two years just as inflation jumped.

  • Reuters

    UPDATE 3-GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology

    GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines. GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.

  • Reuters

    GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology

    (Reuters) -GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines. GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.